We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Dare Bioscience Inc | NASDAQ:DARE | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.0135 | 4.39% | 0.321 | 0.3236 | 0.3299 | 0.39 | 0.3133 | 0.32 | 1,875,835 | 00:58:57 |
Delaware
(State or other jurisdiction of
incorporation or organization)
|
|
20-4139823
(I.R.S. employer
identification number)
|
|
|
|
3655 Nobel Drive, Suite 260, San Diego, CA
(Address of principal executive offices)
|
|
92122
(Zip code)
|
Large accelerated filer
|
|
o
|
|
Accelerated filer
|
|
o
|
|
|
|
|
|||
Non-accelerated filer
|
|
x
|
|
Smaller reporting company
|
|
x
|
|
|
|
|
|||
|
|
|
|
Emerging growth company
|
|
o
|
(1)
|
Pursuant to Rule 416 under the Securities Act of 1933, this registration statement also covers such number of additional shares of common stock that may become issuable under the plan covered by this registration statement by reason of any stock split, stock dividend, recapitalization, or any other similar transaction effected that results in an increase to the number of outstanding shares of the registrant’s common stock. The 787,336 shares consist of (a) 82,855 shares (the “Shares Subject to Outstanding Options”) subject to outstanding options granted under the Daré Bioscience, Inc. Amended and Restated 2014 Stock Incentive Plan (the “Plan”) and (b) 704,481 shares reserved for future grant or issuance under the Plan (the “Reserved Shares”).
|
(2)
|
Estimated solely for the purpose of computing the registration fee in accordance with Rules 457(c) and 457(h) under the Securities Act of 1933. The proposed maximum offering price per share and the proposed maximum aggregate offering price (a) for the Shares Subject to Outstanding Options are based upon the weighted-average exercise price of the outstanding options, and (b) for the Reserved Shares are based on the average of the high and the low prices per share of the registrant’s common stock as reported on the Nasdaq Capital Market as of a date (March 30, 2020) within five business days prior to the filing of this registration statement. The table below details the calculations of the registration fee:
|
Securities
|
No. of
shares
|
Proposed
maximum
offering price
per share
|
Proposed
maximum
aggregate
offering price
|
Shares Subject to Outstanding Options
|
82,855
|
$1.03
|
$85,341
|
Reserved Shares
|
704,481
|
$0.84
|
$591,764
|
Total
|
787,336
|
N/A
|
$677,105
|
Item 8.
|
Exhibits.
|
|
|
|
|
Incorporated by Reference
|
|
|
||||||
Exhibit
No.
|
|
Exhibit Description
|
|
Form
|
|
File No.
|
|
Exhibit
|
|
Filing
Date
|
|
Filed
Herewith
|
5.1
|
|
|
|
|
|
|
|
|
|
|
X
|
|
23.1
|
|
|
|
|
|
|
|
|
|
|
X
|
|
23.2
|
|
|
|
|
|
|
|
|
|
|
X
|
|
24.1
|
|
|
|
|
|
|
|
|
|
|
X
|
|
99.1
|
|
|
Form 8-K
|
|
001-36395-18949535
|
|
10.1
|
|
7/12/2018
|
|
|
|
99.2
|
|
|
Form 10-Q
|
|
001-36395-181013316
|
|
10.3
|
|
8/13/2018
|
|
|
|
99.3
|
|
|
Form 10-Q
|
|
001-36395-181013316
|
|
10.4
|
|
8/13/2018
|
|
|
|
|
|
Daré Bioscience, Inc.
|
||
|
|
|
By:
|
|
/s/ Lisa Walters-Hoffert
|
|
|
Lisa Walters-Hoffert
|
|
|
Chief Financial Officer
|
Signature
|
|
Title
|
|
Date
|
|
|
|
||
/s/ Sabrina Martucci Johnson
|
|
President, Chief Executive Officer, Secretary and Director
|
|
March 30, 2020
|
Sabrina Martucci Johnson
|
|
(Principal Executive Officer) and Director
|
|
|
|
|
|
||
/s/ Lisa Walters-Hoffert
|
|
Chief Financial Officer
|
|
March 30, 2020
|
Lisa Walters-Hoffert
|
|
(Principal Financial and Accounting Officer)
|
|
|
|
|
|
||
/s/ William H. Rastetter
|
|
Chairman of the Board
|
|
March 30, 2020
|
William H. Rastetter, Ph.D.
|
|
|
|
|
|
|
|
||
/s/ Cheryl R. Blanchard
|
|
Director
|
|
March 30, 2020
|
Cheryl R. Blanchard, Ph.D.
|
|
|
|
|
|
|
|
||
/s/ Jessica D. Grossman
|
|
Director
|
|
March 30, 2020
|
Jessica D. Grossman, M.D.
|
|
|
|
|
|
|
|
|
|
/s/ Susan L. Kelley
|
|
Director
|
|
March 30, 2020
|
Susan L. Kelley, M.D.
|
|
|
|
|
|
|
|
||
/s/ Gregory W. Matz
|
|
Director
|
|
March 30, 2020
|
Gregory W. Matz
|
|
|
|
|
|
|
|
||
/s/ Robin J. Steele
|
|
Director
|
|
March 30, 2020
|
Robin J. Steele, J.D., L.L.M.
|
|
|
|
|
1 Year Dare Bioscience Chart |
1 Month Dare Bioscience Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions